Figure 2

Inhibition of IL-1β-induced PAR-2 expression by p38 MAPK inhibitor but not by MEK or JNK MAPK inhibitor and TGF-β1 suppresses PAR-2 protein level induced by IL-1β in h PSCs. (A) h PSCs were pre-treated with 5 μM of U0126, SP600125, and SB202190 in serum-free DMEM for 1 hour and then incubated with 10 ng/ml of IL-1β for 12 hours in serum-free DMEM (n = 3). Lane 1 as basal control and lane 2 as positive control, lane 3 to lane 5 were compared with positive control. (B) h PSCs were pre-treated with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes and then incubated with 2, 5, 10, and 30 ng/ml of TGF-β1 in serum-free DMEM for 12 hours (n = 3). Lane 1 as basal control and lane 2 as positive control, lane 3 to lane 6 were compared with basal control. (C) h PSCs were pre-treated with 10 ng/ml of IL-1β in serum-free DMEM for 30 minutes and then incubated with 10 ng/ml of TGF-β1 for 12, 24, and 48 hours in serum-free DMEM (n = 3). Lane 1 as basal control and lane 2, 4, and 6 as positive controls of lane 3, 5, and 7. Lane 2, 4, and 6, were compared with basal control; lane 3 was compared with lane 2; Lane 5 was compared with lane 4; and lane 7 was compared with lane 6.